Preliminary laboratory studies indicate that two doses of the Pfizer/BioNTech vaccine may not provide sufficient protection against the Omicron variant of the coronavirus, but three doses are capable of neutralizing it, according to the company.
The pharmaceutical firms, in a statement released today, said that a group of patients who had received two doses of the COVID-19 vaccine showed 25 times less efficacy against the Omicron variant than against the virus in its previous variant.
That “indicates that two doses of the BNTA162B2 vaccine may not be sufficient to protect against infection with the Omicron variant,” the statement said.
But preliminary data also indicate that “protection improves with a third dose of our vaccine,” said Pfizer President Albert Bourla.
For his part, Uğur Şahin, president of BioNTech, declared that the first data indicate that a third dose could offer a sufficient level of protection against the disease in any degree of severity caused by the Omicron variant.
This is despite the fact that no deaths from the Omicron variant have yet been recorded, and several specialists have even stated that there are no indications to believe that it is more serious than the Delta variant.